HALO (Halozyme Therapeutics) Total Current Liabilities: $363 Mil (As of Mar. 2026)


HALO Halozyme Therapeutics Inc HALO
92 GF Score
Price $79.47
GF Value $90.71
Valuation Modestly Undervalued
! 3 Warning Signs
View Full Analysis

What is Halozyme Therapeutics Total Current Liabilities?

Halozyme Therapeutics HALO +3.17% 92 Total Current Liabilities is $363 Mil as of Mar. 2026. GuruFocus rates HALO with a GF Score™ of 92/100 and a GF Value™ of $90.71 (Modestly Undervalued). The stock has 3 warning signs investors should review.

Total current liabilities includes Accounts Payable & Accrued Expense, Short-Term Debt & Capital Lease Obligation, Other Current Liabilities, and Current Deferred Liabilities. Halozyme Therapeutics's total current liabilities for the quarter that ended in Mar. 2026 was $363

Be Aware

Stay away from companies that roll over the debt e.g. Bear Stearns

When investing in financial institutions, Buffett shies from those who are bigger borrowers of short term than long term debt.

His favorite Wells Fargo has 57 cents short term debt for every dollar of long term.

Aggressive banks (like Bank of America) has $2.09 short term for every dollar long term

Halozyme Therapeutics Total Current Liabilities Related Terms

Halozyme Therapeutics Total Current Liabilities Historical Data

* Premium members only.

The historical data trend for Halozyme Therapeutics's Total Current Liabilities can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Halozyme Therapeutics Total Current Liabilities Chart

Halozyme Therapeutics Annual Data
Trend Dec16 Dec17 Dec18 Dec19 Dec20 Dec21 Dec22 Dec23 Dec24 Dec25
Total Current Liabilities
Get a 7-Day Free Trial Premium Member Only Premium Member Only 117.15 130.79 112.49 139.10 177.09

Halozyme Therapeutics Quarterly Data
Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23 Mar24 Jun24 Sep24 Dec24 Mar25 Jun25 Sep25 Dec25 Mar26
Total Current Liabilities Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 150.38 134.28 837.23 177.09 363.21
HALO
92GF Score
Halozyme Therapeutics Inc HALO
Total Current Liabilities is just one metric. See GF Score™, valuation, warning signs, and more.
View Full Analysis

Halozyme Therapeutics Total Current Liabilities Calculation

Total Current Liabilities is the total amount of liabilities that the company needs to pay over the next 12 months.

Halozyme Therapeutics's Total Current Liabilities for the fiscal year that ended in Dec. 2025 is calculated as

Total Current Liabilities=Accounts Payable & Accrued Expense+Short-Term Debt & Capital Lease Obligation
=177.092+0
+Other Current Liabilities+Current Deferred Liabilities
=0+0
=177

Halozyme Therapeutics's Total Current Liabilities for the quarter that ended in Mar. 2026 is calculated as

Total Current Liabilities=Accounts Payable & Accrued Expense+Short-Term Debt & Capital Lease Obligation
=154.467+208.743
+Other Current Liabilities+Current Deferred Liabilities
=-5.6843418860808E-14+0
=363

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

The increase of Total Current Liabilities of a company is not necessarily a bad thing. This may conserve the company's cash and contribute positively to cash flow.

Total Current Liabilities is linked to Total Current Assets through the Current Ratio and Working Capital. The Current Ratio is equal to dividing total current assets by total current liabilities. It is frequently used as an indicator of a company's liquidity, its ability to meet short-term obligations. Net working capital is calculated as Total Current Assets minus Total Current Liabilities.

What does a Total Current Liabilities of $363 Mil mean?
Halozyme Therapeutics (HALO) has a Total Current Liabilities of $363 Mil as of Mar. 2026. The total amount of liabilities with maturity less than one year as recorded on a company's balance sheet. View historical data for Halozyme Therapeutics and its competitors.
Is Halozyme Therapeutics' Total Current Liabilities too high?
Halozyme Therapeutics' current Total Current Liabilities is $363 Mil. Overall, Halozyme Therapeutics has a GF Score™ of 92/100 and is considered Modestly Undervalued, reflecting its overall financial health beyond just this single metric.
How does Halozyme Therapeutics' Total Current Liabilities compare to KYMR and IBRX?
Halozyme Therapeutics' Total Current Liabilities of $363 Mil can be compared against companies in the Biotechnology industry. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Total Current Liabilities for a Biotechnology company?
A good Total Current Liabilities depends on the Biotechnology industry context. However, Total Current Liabilities should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Total Current Liabilities mean?
A high Total Current Liabilities can signal that a stock is expensive relative to its fundamentals. The total amount of liabilities with maturity less than one year as recorded on a company's balance sheet. View historical data for Halozyme Therapeutics and its competitors. Halozyme Therapeutics's current Total Current Liabilities is $363 Mil. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Halozyme Therapeutics stock overvalued right now?
Based on GuruFocus' analysis, Halozyme Therapeutics (HALO) is currently considered Modestly Undervalued. The stock's GF Value™ is $90.71, compared to a current price of $79.47 — trading 12.4% below its estimated fair value. The current Total Current Liabilities is $363 Mil. Halozyme Therapeutics' overall GF Score™ is 92/100 with 3 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Total Current Liabilities calculated?
Total Current Liabilities is calculated from a company's financial statements. For Halozyme Therapeutics (HALO), the current Total Current Liabilities is $363 Mil as of Mar. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.

Is Halozyme Therapeutics (HALO) Overvalued in 2026?

Based on GuruFocus' analysis, Halozyme Therapeutics stock appears to be undervalued. The current stock price of $79.47 is trading 12.4% below its estimated GF Value™ of $90.71. GuruFocus considers Halozyme Therapeutics to be Modestly Undervalued.

Key valuation signals for HALO:

  • Total Current Liabilities: $363 Mil
  • GF Value™: $90.71 vs. price of $79.47 (12.4% below fair value)
  • GF Score™: 92/100 with 3 warning signs

No single metric tells the full story. See the HALO stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.

Halozyme Therapeutics Business Description

Address 12390 El Camino Real, San Diego, CA, USA, 92130
Halozyme Therapeutics Inc is a biotechnology company focused on developing and commercializing novel oncology therapies. The company seeks to create therapies focused on human enzymes that alter tumors. Halozyme focuses on developing its proprietary products in therapeutic areas with a focus on oncology, and licensing its technology to biopharmaceutical companies to collaboratively develop products. ENHANZE drug delivery technology was introduced with the proprietary enzyme rHuPH20, to facilitate the subcutaneous delivery of injected drugs and fluids, with the goal of improving the patient experience with rapid SC delivery and reduced treatment burden. The company's operations are based in the United States, with minimal long-lived assets located internationally.
92GF Score

Get the complete analysis for HALO

Total Current Liabilities is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

$79.47
Price
$90.71
GF Value